Prevention of Recurrent Disease

Since the herpes simplex viruses, particularly the genital strain, are responsible for millions of cases of infection and reinfection each year, it is clear that an even larger need exists for an effective method of treatment. Evidence is mounting that resistance of HSV to this acyclovir type drugs is increasing. AuRx intends to press ahead as rapidly as funding will permit to commercialize the AuRx therapeutic vaccine.